4.4 Article

Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma

Journal

GENES CHROMOSOMES & CANCER
Volume 58, Issue 8, Pages 558-566

Publisher

WILEY
DOI: 10.1002/gcc.22737

Keywords

papillary thyroid carcinoma; rearrangement; RNA-Seq; transcript fusion

Funding

  1. Slaska BIO-FARMA. Centrum Biotechnologii, Bioinzynierii i Bioinformatyki [POIG.02.01.00-00-166/08]
  2. Polish National Center of Research and Development [STRATEGMED2/267398/4/NCBR/2015]
  3. PL-Grid Infrastructure
  4. Polish National Science Center [DEC-2011/03/N/NZ2/03495]

Ask authors/readers for more resources

Papillary thyroid carcinoma (PTC) is most common among all thyroid cancers. Multiple genomic alterations occur in PTC, and gene rearrangements are one of them. Here we screened 14 tumors for novel fusion transcripts by RNA-Seq. Two samples harboring RET/PTC1 and RET/PTC3 rearrangements were positive controls whereas the remaining ones were negative regarding the common PTC alterations. We used Sanger sequencing to validate potential fusions. We detected 2 novel potentially oncogenic transcript fusions: TG-FGFR1 and TRIM33-NTRK1. We detected 4 novel fusion transcripts of unknown significance accompanying the TRIM33-NTRK1 fusion: ZSWIM5-TP53BP2, TAF4B-WDR1, ABI2-MTA3, and ARID1B-PSMA1. Apart from confirming the presence of RET/PTC1 and RET/PTC3 in positive control samples, we also detected known oncogenic fusion transcripts in remaining samples: TFG-NTRK1, ETV6-NTRK3, MKRN1-BRAF, EML4-ALK, and novel isoform of CCDC6-RET.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available